[go: up one dir, main page]

MX2022000085A - Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. - Google Patents

Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.

Info

Publication number
MX2022000085A
MX2022000085A MX2022000085A MX2022000085A MX2022000085A MX 2022000085 A MX2022000085 A MX 2022000085A MX 2022000085 A MX2022000085 A MX 2022000085A MX 2022000085 A MX2022000085 A MX 2022000085A MX 2022000085 A MX2022000085 A MX 2022000085A
Authority
MX
Mexico
Prior art keywords
conditions
age
related diseases
gene therapy
therapy methods
Prior art date
Application number
MX2022000085A
Other languages
English (en)
Inventor
George M Church
Noah Davidsohn
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2022000085A publication Critical patent/MX2022000085A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Se proporcionan métodos de terapia génica para el tratamiento o prevención de enfermedades o condiciones relacionadas con la edad para regular una o más proteínas funcionales asociadas con enfermedades o condiciones relacionadas con la edad.
MX2022000085A 2016-05-20 2018-11-20 Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. MX2022000085A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339182P 2016-05-20 2016-05-20
US201662421665P 2016-11-14 2016-11-14

Publications (1)

Publication Number Publication Date
MX2022000085A true MX2022000085A (es) 2022-02-10

Family

ID=60326179

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018014256A MX2018014256A (es) 2016-05-20 2017-05-22 Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
MX2025014039A MX2025014039A (es) 2016-05-20 2018-11-20 Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad
MX2022000085A MX2022000085A (es) 2016-05-20 2018-11-20 Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2018014256A MX2018014256A (es) 2016-05-20 2017-05-22 Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
MX2025014039A MX2025014039A (es) 2016-05-20 2018-11-20 Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad

Country Status (9)

Country Link
US (2) US12281154B2 (es)
EP (1) EP3458585A4 (es)
JP (4) JP7632835B2 (es)
CN (2) CN109844124B (es)
AU (2) AU2017268469C1 (es)
BR (1) BR112018073861A2 (es)
CA (1) CA3025020A1 (es)
MX (3) MX2018014256A (es)
WO (1) WO2017201527A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3582797A1 (en) * 2017-02-14 2019-12-25 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Naf-1 derived peptides and uses thereof
MX2019011040A (es) * 2017-03-17 2020-01-20 Adverum Biotechnologies Inc Composiciones y metodos para potenciar la expresion genica.
BR112019024608A2 (pt) * 2017-05-24 2020-06-23 Universitat Autonoma De Barcelona Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21)
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
US11530433B2 (en) * 2017-10-20 2022-12-20 President And Fellows Of Harvard College Artificial secretion peptides for heterologous protein production
WO2019113061A1 (en) * 2017-12-06 2019-06-13 Klogene Therapeutics, Inc. Compositions and methods for modulating gene expression
SG11202101819QA (en) * 2018-08-30 2021-03-30 Res Inst Nationwide Childrens Hospital Gene therapy for the treatment of galactosemia
MX2021004313A (es) * 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
US12134772B2 (en) 2018-11-21 2024-11-05 Advantage Therapeutics, Inc. Increasing gene expression
KR20210096128A (ko) * 2018-11-26 2021-08-04 유니버시타트 아우토노마 데 바르셀로나 섬유아세포 성장 인자 21(fgf21) 유전자 요법
US12203070B2 (en) 2019-05-23 2025-01-21 Christiana Care Gene Editing Institute, Inc. Gene knockout of NRF2 for treatment of cancer
JP7585237B2 (ja) 2019-05-23 2024-11-18 クリスティアナ ケア ジーン エディティング インスティテュート，インコーポレーテッド がんを処置するためのバリアントｎｒｆ２の遺伝子ノックアウト
CN114207135A (zh) 2019-06-11 2022-03-18 夏尔人类遗传性治疗公司 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送
US10653731B1 (en) * 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
KR102281858B1 (ko) * 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
KR20220079857A (ko) * 2019-09-13 2022-06-14 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 Aav-상용성 라미닌-링커 중합 단백질
CN115176022A (zh) 2019-10-23 2022-10-11 夏尔人类遗传性治疗公司 用于遗传性血管性水肿的基于腺相关病毒载体的基因疗法
CN110894508B (zh) * 2019-10-31 2021-08-06 内蒙古大学 一种调控白色脂肪棕色化的基因Adra1a的应用
AU2020398637A1 (en) * 2019-12-05 2022-06-30 President And Fellows Of Harvard College Methods for treating osteoarthritis
JP7588466B2 (ja) * 2020-01-22 2024-11-22 旭化成メディカル株式会社 パルボウイルスの生産方法
WO2021222476A2 (en) * 2020-04-28 2021-11-04 President And Fellows Of Harvard College High efficiency gene delivery system
CA3182915A1 (en) * 2020-05-13 2021-11-18 Lysogene Compositions and methods for treating gm1 gangliosidosis and other disorders
JP2023528590A (ja) * 2020-05-26 2023-07-05 ウニベルシダッド アウトノマ デ バルセロナ 中枢神経系障害に対する線維芽細胞増殖因子２１（ｆｇｆ２１）遺伝子治療
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途
WO2022115739A2 (en) * 2020-11-30 2022-06-02 Cellular Longevity, Inc. Lnp and liposome compositions for longevity in mammals and methods of using the same
EP4263614A1 (en) 2020-12-16 2023-10-25 Takeda Pharmaceutical Company Limited Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
KR102590276B1 (ko) * 2021-01-04 2023-10-16 부산대학교 산학협력단 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113088531B (zh) * 2021-03-25 2023-10-17 四川省药品检验研究院(四川省医疗器械检测中心) 牛源性成分定量分析标准质粒、制备及检测方法及应用
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
JP2022169389A (ja) * 2021-04-27 2022-11-09 国立大学法人北海道大学 イヌＴＧＦ－β受容体ＩＩ
US20220401583A1 (en) * 2021-06-16 2022-12-22 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
US20230018934A1 (en) * 2021-07-16 2023-01-19 Genflow Biosciences Srl Method of in vivo administration of the coding sequence of the sirt6 gene via adeno-associated virus
US20240384245A1 (en) * 2021-09-29 2024-11-21 Sirt6 Ltd Method for treating a disease
CN114921480A (zh) * 2022-06-09 2022-08-19 国科宁波生命与健康产业研究院 一种骨细胞Terc基因敲除小鼠模型的构建方法
WO2024064785A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for familial partial lipodystrophy
WO2024064784A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for treating mitral valve disease
WO2024064796A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for arrhythmogenic cardiomyopathy
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物
WO2025109173A1 (en) 2023-11-22 2025-05-30 Advantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
EP4566618A1 (en) * 2023-12-06 2025-06-11 ADvantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
WO2026002276A1 (zh) * 2024-06-28 2026-01-02 艾码生物科技(南京)有限公司 靶向tgfb的rna干扰方法、核酸及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
PL336306A1 (en) 1997-04-18 2000-06-19 Biogen Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US7419829B2 (en) * 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
AU2003209226A1 (en) 2002-01-11 2003-07-30 Michael Tennant Adiponectin gene therapy
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
EP1812450A2 (en) * 2004-11-10 2007-08-01 Eli Lilly And Company Tgf-beta inhibitors
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
EA016038B1 (ru) * 2005-04-22 2012-01-30 Эли Лилли Энд Компани Антитело к tgf-бета и его применение
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
US20070292922A1 (en) 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2008088401A2 (en) * 2006-09-13 2008-07-24 The Trustees Of Columbia University In The City Of New York Methods for identifying, or assaying for agents that increase beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
JP2010529859A (ja) * 2007-06-15 2010-09-02 ジェンザイム、コーポレーション ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
US8236557B2 (en) 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
DK2542590T4 (da) * 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
ES2423798T3 (es) * 2010-11-19 2013-09-24 Universitätsklinikum Freiburg Hidrogeles de PEG disolubles sensibles a estímulos biofuncionalizados
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
MX2014002260A (es) * 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
US9006400B2 (en) * 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
CN103203027A (zh) 2011-11-03 2013-07-17 阳明大学 用于治疗和预防老化相关症状的方法和组分
US9422561B2 (en) 2012-01-24 2016-08-23 Bar-Ilan University Treatment of disease by modulation of SIRT6
CN103665166A (zh) * 2012-09-03 2014-03-26 福又达生物科技股份有限公司 犬融合干扰素
WO2014152993A1 (en) 2013-03-14 2014-09-25 The Board Of Regents Of The University Of Oklahoma Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions
WO2015157469A2 (en) * 2014-04-08 2015-10-15 University Of Southern California Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing
KR20150135148A (ko) * 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
CN114805531A (zh) * 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10882894B2 (en) * 2015-08-11 2021-01-05 Anie Philip Peptidic TGF-beta antagonists

Also Published As

Publication number Publication date
CN109844124A (zh) 2019-06-04
CN117535350A (zh) 2024-02-09
JP2022033855A (ja) 2022-03-02
AU2017268469C1 (en) 2025-01-02
JP2023078338A (ja) 2023-06-06
MX2025014039A (es) 2026-01-07
AU2024219991A1 (en) 2024-10-10
CN109844124B (zh) 2023-10-03
JP2025078652A (ja) 2025-05-20
BR112018073861A2 (pt) 2019-02-26
AU2017268469B2 (en) 2024-07-25
US12281154B2 (en) 2025-04-22
JP7632835B2 (ja) 2025-02-19
WO2017201527A3 (en) 2018-02-08
EP3458585A4 (en) 2019-10-30
JP2019519221A (ja) 2019-07-11
US20190345224A1 (en) 2019-11-14
JP7315284B2 (ja) 2023-07-26
EP3458585A2 (en) 2019-03-27
CA3025020A1 (en) 2017-11-23
AU2017268469A1 (en) 2019-01-03
WO2017201527A2 (en) 2017-11-23
US20250122267A1 (en) 2025-04-17
MX2018014256A (es) 2019-08-16

Similar Documents

Publication Publication Date Title
MX2022000085A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
PH12019502724A1 (en) Compositions for modulating c9orf72 expression
ZA201903327B (en) Compositions and methods for the induction of cd8+ t¿cells
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
PH12018500964A1 (en) Modified friedreich ataxia genes and vectors for gene therapy
MX2018005286A (es) Constructo genetico.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
ZA201803661B (en) Compositions and methods for decreasing tau expression
CR20160480A (es) Terapia genetica para la retinitis pigmentaria
MX2022012386A (es) Compuestos inhibidores de metaloenzimas.
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
MX2018015172A (es) Metodos para tratar cancer pancreatico.
ZA201807438B (en) Methods of treating ocular conditions
TW201613587A (en) Medical treatments based on anamorelin
ZA201703467B (en) Methods of treating ocular conditions
WO2018125799A3 (en) Metalloenzyme inhibitor compounds
MX2018013885A (es) Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
EP3402531A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP4324476A3 (en) Methods for treating relapsing forms of multiple sclerosis
HK40016058A (en) Methods of treating diseases associated with ilc2 cells